

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



KRSNAA DIAGNOSTICS LIMITED

Krsnaa Diagnostics Limited (our "Company" or the "Issuer") was originally incorporated as 'Krsna Diagnostics Private Limited' at Pune, Maharashtra as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated December 22, 2010, issued by the Registrar of Companies, Maharashtra at Pune ("RoC"). The name of our Company was subsequently changed to 'Krsnaa Diagnostics Private Limited', pursuant to a fresh certificate of incorporation issued by the RoC on January 29, 2015. Thereafter, our Company was converted into a public limited company pursuant to a special resolution passed in the extraordinary general meeting of the Shareholders of our Company held on April 25, 2021 and consequently the name of our Company was changed to its present name pursuant to a fresh certificate of incorporation issued by the RoC on May 6, 2021. For further details relating to the changes in the name of our Company and the registered office of our Company, see "History and Certain Corporate Matters" on page 168 of the Red Herring Prospectus dated July 29, 2021 ("RHP").

Registered and Corporate Office: S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka – Haveli, Pune - 411 019, Maharashtra; **Telephone:** +91 20 4695 4695; **Contact Person:** Manisha Chitgopekar, Company Secretary and Compliance Officer; **Telephone:** +91 20 4695 4695; **E-mail:** cs@krsnadiagnostics.com; **Website:** www.krsnadiagnostics.com, **Corporate Identity Number:** U74900PN2010PLC138068;

OUR PROMOTER: RAJENDRA MUTHA

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹5 EACH ("EQUITY SHARES") OF OUR COMPANY FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION ("OFFER"). THE OFFER COMPRISES OF A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹4,000.00 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 8,525,520 EQUITY SHARES ("OFFERED SHARES") AGGREGATING UP TO ₹[●] MILLION, COMPRISING UP TO 1,600,000 EQUITY SHARES AGGREGATING TO ₹[●] MILLION BY PHI CAPITAL TRUST-PHI CAPITAL GROWTH FUND-I, ("SELLING SHAREHOLDER 1"), UP TO 3,340,713 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY KITARA PIIN 1104 ("SELLING SHAREHOLDER 2"), UP TO 3,563,427 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY SOMERSET INDUS HEALTHCARE FUND I LIMITED ("SELLING SHAREHOLDER 3") AND UP TO 21,380 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY LOTUS MANAGEMENT SOLUTIONS (ACTING THROUGH MAYUR SIRDESAI) ("SELLING SHAREHOLDER 1, SELLING SHAREHOLDER 2 AND SELLING SHAREHOLDER 3, THE "SELLING SHAREHOLDERS" AND SUCH OFFER, THE "OFFER FOR SALE". THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹200.00 MILLION, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (AS DEFINED HEREINAFTER) (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE [●]% AND [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY.

Retail Individual Bidders Portion: Not More than 10% of the Net Offer

QIB Portion: Not Less than 75% of the Net Offer

Non-Institutional Bidders Portion: Not More than 15% of the Net Offer

Employee Reservation Portion: Upto ₹ 200 million

Price Band: ₹ 933 to ₹ 954 per Equity Share of face value of ₹5 each.

The Floor Price is 186.60 times the face value of the Equity Shares and the Cap Price is 190.80 times the face value of the Equity Shares.

Bids can be made for a minimum of 15 Equity Shares and in multiples of 15 Equity Shares thereafter.

A Discount of ₹ 93 per Equity Share is being Offered to Eligible Employees Bidding in the Employee Reservation Portion.

ASBA[#]

Simple, Safe,
Smart way of Application!!!

Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, For further details, check section on ASBA below.
Mandatory in public issues. No cheque will be accepted.



UPI-Now available in ASBA for Retail Individual Bidders ("RIBs") applying through Registered Brokers, Syndicate, DPs and RTAs. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.
Bidders are required to ensure that the bank account used for bidding is linked to their PAN.

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by Retail Individual Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Offer Procedure" on page 355 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of www.sebi.gov.in. ICICI Bank Limited has been appointed as Sponsor Bank for the Offer, in accordance with the requirements of the SEBI UPI Circular dated November 1, 2018 as amended. For Offer related queries or UPI related queries, investors may contact: JM Financial Limited - Prachee Dhuri (+ 91 22 6630 3030) (krsnadiagnostics ipo@jmf.com, grievance.ibd@jmf.com); DAM Capital Advisors Limited (Formerly IDFC Securities Limited) - Chandresh Sharma (+91 22 4202 2500) (krsnaa ipo@damcapital.in, complaint@damcapital.in); Equirus Capital Private Limited - Ankesh Jain (+91 22 4332 0700) (krsnaa ipo@equirus.com, investorsgrievance@equirus.com); IIFL Securities Limited - Aditya Agarwal / Harshvardhan Jain (+91 22 4646 4600) (krsnaa ipo@iiflcap.com, ig_ib@iiflcap.com). For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail Id: ipo.upi@npci.org.in; ICICI Bank Limited at Tel: +91 22 6681 8911/23/24 and Email: kmr.saurabh@icicibank.com; and the Registrar to the Offer at Tel: +91 40 6716 2222 and Email: krsnaa ipo@kfintech.com or einward.ris@kfintech.com.

Risks to Investors

- The 4 Book Running Lead Managers associated with the Offer have handled 32 public issues in the past three years, out of which 10 issues closed below the offer price on listing date.
- Average cost of acquisition of Equity Shares held by the Selling Shareholder PHI CAPITAL TRUST-PHI CAPITAL GROWTH FUND-I, Kitara PIIN 1104, SOMERSET INDUS HEALTHCARE FUND I LIMITED and LOTUS MANAGEMENT SOLUTIONS (ACTING THROUGH MAYUR SIRDESAI) is ₹ 157.26 per Equity Share, ₹ 67.35 per Equity Share, ₹ 67.35 per Equity Share and ₹ 67.35 per Equity Share, respectively and Offer Price at upper end of the Price Band is ₹ 954 per Equity Share.
- Weighted Average Return on Net Worth for Fiscals 2021, 2020 & 2019 is 9.54%.

BASIS FOR OFFER PRICE

The Offer Price will be determined by our Company and the Selling Shareholders, in consultation with the BRLMs, on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹5 each and the Offer Price is 186.60 times the face value at the lower end of the Price Band and 190.80 times the face value at the higher end of the Price Band.

Bidders should read the below mentioned information along with "Our Business", "Risk Factors", "Restated Financial Statements" and "Management's Discussion and Analysis of Financial Position and Results of Operations" on pages 142, 24, 201 and 288, respectively of the RHP, to have an informed view before making an investment decision.

Qualitative Factors: We believe that some of the qualitative factors which form the basis for computing the Offer Price are as follows: • Unique and scaled diagnostics company; • Strong brand equity; • Extensive footprint across India with robust infrastructure; • Business model with robust revenue visibility; • Well positioned to capitalize on healthcare spending across public and private sectors. For further details, see "Our Business – Strengths" on page 144 of the RHP.

Quantitative Factors: Certain information presented below, relating to our Company, is based on the Restated Financial Statements. For details, see "Restated Financial Statements" on page 201 of the RHP.

Some of the quantitative factors which may form the basis for computing the Offer Price are as follows:

1. Basic and Diluted Earnings Per Share ("EPS"), as adjusted for changes in capital:

Financial Period Basic	Basic EPS (in ₹)	Diluted EPS (in ₹)	Weight
Financial Year 2021	71.66	12.25	3
Financial Year 2020	(43.53)	(43.53)	2
Financial Year 2019	(24.13)	(24.13)	1
Weighted Average	17.40	(12.41)	

Notes:

- The Weighted Average basic and diluted EPS is a product of basic and diluted EPS and respective assigned weight, dividing the resultant by total aggregate weight. Weights applied have been determined by the management of the Company.
- Basic EPS (in ₹) = $\frac{\text{Restated adjusted Profit/(loss) for the year/period for Basic EPS}}{\text{Weighted Average no. of equity shares outstanding during the year/period}}$
- Diluted EPS (in ₹) = $\frac{\text{Restated Profit/(Loss) after tax for the year/period}}{\text{Weighted Average no. of equity shares and potential equity shares outstanding during the year/period}}$
- Basic EPS and Diluted EPS calculations are in accordance with the relevant accounting standard and post conversion of Series B CCCPS on March 31, 2021, have been adjusted for split of Equity Shares on April 25, 2021 and post conversion of Series A CCCPS and Series C CCCPS on July 23, 2021.

2. Price/Earning ("P/E") ratio in relation to Price Band of ₹ 933 to ₹ 954 per Equity Share:

Particulars	P/E at the Floor Price (no. of times)	P/E at the Cap Price (no. of times)
Based on Basic EPS for Financial Year 2021	12.98	13.28
Based on Diluted EPS for Financial Year 2021	76.16	77.88

Industry P/E ratio

Particulars	P/E Ratio
Highest	94.32
Lowest	77.65
Industry Composite	85.99

Notes: (1) The industry high and low has been considered from the industry peer set provided later in this chapter. The industry composite has been calculated as the arithmetic average P/E of the industry peer set disclosed in this section. For further details, see "Comparison of Accounting Ratios with Listed Industry Peers" on page 109 of the RHP.

3. Return on Net Worth ("RoNW")

As per the Restated Financial Statements of our Company:

Particulars	RoNW %	Weight
Financial Year 2021	79.76	3
Financial Year 2020	(56.83)	2
Financial Year 2019	(68.37)	1
Weighted Average	9.54	

- Notes: 1. Return on Net Worth (%) = $\frac{\text{Restated net profit after tax for the year/period attributable to the equity Shareholders of the Company}}{\text{Restated net worth for the year/period end}}$
2. The weighted average return on net worth is a product of return on net worth and respective assigned weight dividing the resultant by total aggregate weights.
3. Net worth for the ratios represents sum of equity share capital, instruments entirely equity in nature and other equity which comprises of Employee Stock options outstanding account, securities premium, surplus/(deficit) in the Statement of Profit and Loss and other reserves, as restated.

4. Net Asset Value per Equity Share of face value of ₹ 5 each

Net Asset Value per Equity Share	(₹)
As on March 31, 2021	85.27
After the Offer	
At Floor Price	200.58
At Cap Price	201.19
Offer Price	[●]

Notes: 1. Net Asset Value per Equity Share is calculated post conversion of Series B CCCPS on March 31, 2021, has been adjusted for split of Equity Shares on April 25, 2021 and post conversion of Series A CCCPS and Series C

CCPS on July 23, 2021. Offer Price per Equity Share will be determined on conclusion of the Book Building Process.
2. Net Asset Value per Equity Share = $\frac{\text{Restated net worth at the end of the year/period divided by the Equity shares outstanding at the end of year/period}}{\text{}}$

5. Comparison of Accounting Ratios with Listed Industry Peers

Name of Company	Face Value (₹ per share)	Revenue, for Financial Year 2021 (in ₹ million)	EPS, for Financial Year 2021 (₹)		NAV, as on March 31, 2021 ^{(2)(d)} (₹ per share)	P/E ⁽¹⁾	RoNW, as on March 31, 2021 ⁽³⁾ (%)	EBITDA	Current Maturities of Long Term Debt	Debt Service Ratio ⁽⁴⁾
			Basic	Diluted ⁽¹⁾						
Krsnaa Diagnostics Limited	5	3,964.56	71.86**	12.25**	85.27**	1.01	79.76	1,060.47*	290.81	3.65x
Listed Peers										
Metropolis Healthcare Limited	2	9,979.87	35.97	35.79	138.23	77.65	25.91	2,880.00	-	-
Dr. Lal PathLabs Limited	10	15,812.66	35.33	35.25	149.39	94.32	23.42	4,363.00	-	-

*Adjusted EBITDA

** Basic and Diluted EPS and NAV is calculated post conversion of Series A CCCPS and Series C CCCPS.

Source: All the financial information for listed industry peer mentioned above is on a consolidated basis and is sourced from the annual report of the company for the year ended March 31, 2021.

Notes: 1. For our Company: Based on the Restated Financial Statements for the year ended March 31, 2021.

(a) P/E Ratio has been computed based on the closing market price of equity shares on BSE on July 22, 2021, divided by the Basic EPS.

(b) RoNW is computed as net profit after tax (excluding profit attributable to non-controlling interest) divided by closing net worth.

(c) Net worth has been computed as sum of paid-up share capital and other equity.

(d) NAV is computed as the closing net worth divided by the closing outstanding number of equity shares.

(e) Debt Service Ratio = EBITDA / Current maturities of Long term debt (repayments due within next 12 months)

The Offer Price of ₹[●] has been determined by our Company and the Selling Shareholders, in consultation with the Book Running Lead Managers, on the basis of assessment of market demand from investors for Equity Shares through the Book Building Process and is justified in view of the above qualitative and quantitative parameters. The trading price of Equity Shares could decline due to factors mentioned in "Risk Factors" on page 24 of the RHP and you may lose all or part of your investments.

FOR FURTHER DETAILS, SEE "BASIS FOR OFFER PRICE" BEGINNING ON PAGE 108 OF THE RHP.

BID/OFFER PROGRAMME

OPENS ON : WEDNESDAY, AUGUST 4, 2021⁽¹⁾ | CLOSES ON: FRIDAY, AUGUST 6, 2021^{(2)#}

⁽¹⁾ Our Company and the Selling Shareholders in consultation with the BRLMs may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Offer Opening Date.

⁽²⁾ Our Company and the Selling Shareholders in consultation with the BRLMs may consider closing the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date in accordance with the SEBI ICDR Regulations.

*UPI Mandate end time and date shall be at 12:00 pm on August 9, 2021.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs(s) and at the terminals of the members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in accordance with Regulation 6(2) of the SEBI ICDR Regulations wherein, not less than 75% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"), out of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Net Offer cannot be Allotted to QIBs, the Bid Amounts received by our Company shall be refunded. Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not more than 10% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIBs") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, such Equity Shares aggregating to ₹ 200.00 million will be available for allocation to Eligible Employees, subject to valid Bids being received at or above the Offer Price. All Bidders, other than Anchor Investors, are mandatorily required to participate in the Offer through the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see "Offer Procedure" on page 355 of the RHP.

Bidders/Applicants should note that on the basis of the PAN, DP ID and Client ID and UPI ID (for RIBs bidding through UPI Mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects of the Company, please see the section entitled

"History and Certain Corporate Matters" on page 168 of the RHP and Clause III of the Memorandum of Association of the Company. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section entitled "Material Contracts and Documents for Inspection" on page 400 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and Capital structure: The authorised, issued, subscribed and paid-up share capital of the Company as on the date of the RHP is as follows: The authorised share capital of the Company is ₹ 212,240,000 divided into 42,448,000 Equity Shares of face value of ₹ 5 each, 4,061,914 Series A cumulative convertible preference shares of ₹ 123 each and 3,038,886 Series C cumulative convertible preference shares of ₹ 250 each. The issued, subscribed and paid-up share capital of the Company is ₹ 135,957,640 divided into 27,191,528 Equity Shares of face value of ₹ 5 each. For details, please see the section entitled "Capital Structure" beginning on page 79 of the RHP.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: The names of the signatories of the Memorandum of Association of the Company are Rajendra Mutha and Sunita Mutha, who subscribed to 5,000 equity shares each.

Listing: The Equity Shares offered through the RHP are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to letters dated June 4, 2021 and June 22, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A copy of the RHP and the Prospectus shall be filed with the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the RHP until the Bid/Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 400 of the RHP.

Disclaimer Clause of the SEBI: The Securities and Exchange Board of India ("SEBI") only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 332 of the RHP for the full text of the Disclaimer Clause of SEBI.

Disclaimer Clause of BSE : It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 337 of the RHP for the full text of the Disclaimer Clause of BSE.

Disclaimer Clause of NSE (Designated Stock Exchange) : It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the RHP has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 338 of the RHP for the full text of the Disclaimer Clause of NSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the RHP. Specific attention of the investors is invited to "Risk Factors" on page 24 of the RHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
					<p>Manisha Chitgopekar S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1 Near Chinchwad Station, Chinchwad, Taluka – Haveli, Pune - 411 019, Maharashtra. Telephone: +91 020 4695 4695; E-mail: cs@krsnadiagnostics.com;</p> <p>Investors can contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-offer or post-offer related problems such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all offer related queries and for redressal of complaints, investors may also write to the Lead Managers.</p>
<p>JM Financial Limited 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi Mumbai – 400 025, Maharashtra Telephone: +91 22 6630 3030; +91 22 6630 3262 E-mail: krsnadiagnostics.ipo@jmf.com Website: www.jmf.com Investor grievance e-mail: grievance.ibd@jmf.com Contact person: Prachee Dhuri SEBI registration no.: INM000010361</p>	<p>DAM Capital Advisors Limited (Formerly IDFC Securities Limited) One BKC, Tower C, 15th Floor, Unit No. 1511, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, Maharashtra Telephone: +91 22 4022 2500 E-mail: krsnaa.ipo@damcapital.in Website: www.damcapital.in Investor grievance e-mail: complaint@damcapital.in Contact person: Chandresh Sharma SEBI registration no.: MB/INM000011336</p>	<p>Equirus Capital Private Limited 12th Floor, C Wing, Marathon Futurex, N M Joshi Marg, Lower Panel, Mumbai-400 013, Maharashtra Telephone: +91 22 4332 0700 E-mail: krsnaa.ipo@equirus.com Website: www.equirus.com Investor grievance e-mail: investorsgrievance@equirus.com Contact person: Ankesh Jain SEBI registration no.: INM000011286</p>	<p>IIFL Securities Limited 10th Floor, IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Panel (West), Mumbai-400 013 Maharashtra Telephone: +91 22 4646 4600 E-mail: krsnaa.ipo@iiflcap.com Website: www.iiflcap.com Investor grievance e-mail: ig_ib@iiflcap.com Contact person: Aditya Agarwal / Harshvardhan Jain SEBI registration no.: INM000010940</p>	<p>KFin Technologies Private Limited Selenium Tower B, Plot 31 & 32, Gachibowli Financial District, Nanakramuguda Serlingampally, Hyderabad - 500 032, Telangana Telephone: +91 40 6716 2222 Email: krsnaa.ipo@kfintech.com Website: www.kfintech.com/ Investor grievance e-mail: einward.ris@kfintech.com Contact person: M. Murali Krishna SEBI registration no.: INR000000221</p>	

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the Risk Factors, contained therein before applying in the Issue. Full copy of the RHP is available on website of SEBI at www.sebi.gov.in, website of the BRLMs i.e. JM Financial Limited, DAM Capital Advisors Limited (Formerly IDFC Securities Limited), Equirus Capital Private Limited and IIFL Securities Limited at www.jmf.com, www.damcapital.in, www.equirus.com, and www.iiflcap.com, respectively and on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

AVAILABILITY OF BID CUM APPLICATION FORMS: Bid cum Application Forms can be obtained from the Registered Office of Krsnaa Diagnostics Limited, Telephone: +91 20 4695 4695; BRLMs : JM Financial Limited, Telephone: +91 22 6630 3030; +91 22 6630 3262, DAM Capital Advisors Limited, (Formerly IDFC Securities Limited), Telephone: +91 22 4202 2500, Equirus Capital Private Limited, Telephone: +91 22 4332 0700 and IIFL Securities Limited, Telephone: +91 22 4646 4600 and Syndicate Members : Equirus Securities Private Limited, Telephone: +91 022 6136 3400 and Sharekhan Limited, Telephone: +91 22 6115 0000 at the select locations of the Sub-syndicate Members (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

Sub-Syndicate Members: Almondz Global Securities Ltd, Anand Rathi Shares & Stock Brokers Ltd, Ashika Stock Broking Ltd, Axis Capital Limited, Bajaj Financial Securities Ltd, Centrum Broking Ltd, Edelweiss Broking Ltd, Eureka Stock & Share Broking Services Ltd, Globe Capital Market Ltd, HDFC Securities Ltd, Hem Securities Ltd, ICICI Securities Limited, IDBI Capital Markets and Securities Ltd, JM Financial Services Limited, Keynote Capitals Limited, KJM Capital Market Services Ltd, Kotak Securities Ltd, LKP Securities Limited, Motilal Oswal Financial Services Limited, Nirmal Bang Securities Pvt. Ltd., Prabhudas Lilladher Pvt Ltd, Pravin Ratilal Share And Stock Brokers Ltd., Religare Broking Limited, RR Equity Brokers P. Ltd, SBICAP Securities Ltd., SMC Global Securities Ltd., Tradebulls Securities Ltd and Yes Securities (India) Ltd.

Escrow Collection Bank, Refund Bank, Sponsor Bank and Public Account Bank: ICICI Bank Limited

UPI: Retail Individual Investors can also Bid through UPI mechanism

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: Pune
Date: July 30, 2021

Krsnaa Diagnostics Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an